6th Next-Generation Histone Deacetylase Inhibitors meet - USA

Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) being tested in the pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating CNS, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects.

Program topics will include:
- Understanding the mechanism of HDAC inhibition
- Screening for HDAC inhibition: Use of animal models and in vitro assays
- Using structural biology to guide chemical design
- Challenges with achieving isoform selectivity and specificity
- Evaluating the use of pan versus isoform-specific inhibitors
- Experimenting with monotherapy and combination therapies
- Update on novel HDACi and their progress towards the clinic
- Tracking the progress of HDACi for non-oncology indications
- Targeting Sirtuins: Emerging role in various diseases
- Addressing safety concerns at the pre-clinical and clinical stages
- Developing surrogate biomarkers for patient response and resistance
- Adverse effects in the clinic and issues with patient compliance

Further details and to register